<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594111</url>
  </required_header>
  <id_info>
    <org_study_id>CARB-025-15S</org_study_id>
    <nct_id>NCT02594111</nct_id>
  </id_info>
  <brief_title>Colchicine in Percutaneous Coronary Intervention</brief_title>
  <official_title>Anti-inflammatory Therapy During Percutaneous Coronary Intervention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammation in the arteries of the heart may increase the risk of cardiac death. The
      proposed research seeks to identify the potential beneficial role of a safe anti-inflammatory
      medication, colchicine, on reducing damage caused by opening up a blockage in the arteries of
      the heart. With its quick onset of action and excellent safety profile, colchicine may have
      the potential to reduce risk of major adverse events related to the heart. This research also
      seeks to better understand the role of neutrophils, the most common type of inflammatory
      white blood cell in the body, when there is damage to the heart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will use colchicine as a tool to elucidate the role of neutrophil
      activation during acute vascular injury, and to explore the association between neutrophil
      activation and adverse cardiovascular outcomes. Colchicine reduces cell surface expression of
      selections, adhesion molecules key to neutrophil recruitment after vascular injury. Daily
      colchicine use is associated with reduced adverse cardiovascular events in stable
      atherosclerosis. Using a clinical percutaneous coronary intervention (PCI) model, the
      investigators evaluate whether pre-procedural colchicine (1.8 mg oral load over one hour)
      reduces the rate of post-PCI adverse cardiovascular outcomes in the context of a double-blind
      placebo-controlled randomized study. The investigators will also characterize neutrophil
      biology in acute vascular injury and the effects of colchicine on neutrophil biology in this
      setting.

      This study will extend the investigations from study NCT01709981 on ClinicalTrials.gov, which
      remains double-blinded. However, while the main focus of study NCT01709981 is to evaluate
      markers of inflammation, the current study's main focus will be to evaluate peri-procedural
      myocardial infarction. Although recruitment for the current study will begin in 12/2015, the
      investigators will increase power by using data already collected in from the initial
      substudy NCT01709981.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peri-procedural myocardial necrosis</measure>
    <time_frame>24 hours</time_frame>
    <description>troponin above the ULN</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality, non-fatal MI, or target vessel revascularization (TVR)</measure>
    <time_frame>30 days</time_frame>
    <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality, non-fatal MI, or TVR</measure>
    <time_frame>1 year</time_frame>
    <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality, non-fatal MI, or TVR</measure>
    <time_frame>2 years</time_frame>
    <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality, non-fatal MI, or TVR</measure>
    <time_frame>3 years</time_frame>
    <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality, non-fatal MI, or TVR</measure>
    <time_frame>4 years</time_frame>
    <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality, non-fatal MI, or TVR</measure>
    <time_frame>5 years</time_frame>
    <description>all-cause mortality, non-fatal MI (universal definition), or target vessel revascularization (TVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peri-procedural myocardial infarction (MI)</measure>
    <time_frame>24 hours</time_frame>
    <description>SCAI definition</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Colchicine 1.8 mg PO over 1 hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colchicine vs Placebo</intervention_name>
    <description>Colchicine vs Placebo 1.8 mg PO over 1 hour</description>
    <arm_group_label>Colchicine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Referred for possible PCI

        Exclusion Criteria:

          -  Colchicine use within 1 month

          -  History of colchicine intolerance

          -  Glomerular filtration rate &lt;30mL/minute or on dialysis (due to the need to adjust
             colchicine dose in this setting)

          -  Active malignancy or infection (major confounder with increased inflammatory markers)

          -  History of myelodysplasia (due to suggested cautionary use of colchicine in this
             setting)

          -  High-dose statin load &lt;24 hours prior to procedure (major confounder that is known to
             reduce inflammatory levels in 12 to 24 hours)

          -  Use of anti-inflammatory agents (except aspirin) within 5 halflives of the individual
             drug

          -  Use of strong Cytochrome P450, Family 3, Subfamily A, Polypeptide 4 (CYP3A4) and/or
             P-glycoprotein inhibitors (e.g. ritonavir, ketoconazole, clarithromycin, cyclosporine,
             diltiazem and verapamil, again due to drug interactions)

          -  Unable to consent

          -  Participating in a competing study

          -  Any significant condition or situation that may put the subject at higher risk,
             confound the study results or interfere with adherence to study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Binita Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Binita Shah, MD</last_name>
    <phone>(212) 686-7500</phone>
    <email>Binita.Shah@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Steven P Sedlis, MD</last_name>
    <phone>(212) 951-3335</phone>
    <email>steven.sedlis@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binita Shah, MD</last_name>
      <phone>212-686-7500</phone>
      <email>Binita.Shah@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Steven P Sedlis, MD</last_name>
      <phone>(212) 951-3335</phone>
      <email>steven.sedlis@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>Binita Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2015</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inflammation</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>coronary artery disease</keyword>
  <keyword>colchicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colchicine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

